Alector, Inc. (ALEC)

Alector is a funded but fundamentally weak, high-risk development-stage biotech: collaboration revenue collapsed to $21.0M in FY2025 and fades toward near-zero after GSK's termination, net losses persist ($142.9M in FY2025), stockholders' equity turned negative, and five clinical programs have been terminated leaving no active trials. Solvency is cushioned by $172.8M in cash, a repaid term loan, and the $100M Genentech upfront that extends runway into 2029 - with no going-concern warning - but earnings power is years away and valuation metrics are largely non-meaningful on negative earnings. Speculative, event-driven profile; fundamentals do not support an actionable buy entry now.

Dominant catalyst is Alector's 2026-10-05 global license with Genentech for AL050 ($100M upfront, up to $1.17B milestones; announced confidence) — a market-rewarded, still-being-priced event that has flipped media polarity from negative to bullish. Sentiment delta is determinate positive (baseline -0.17 → scoring +0.39); the Red-Flag Screen is clean with no severe or moderate flags fired; the retail signal is low-confidence (bot-heavy threads, near-zero engagement) and treated as mention-only.

Bounce-only chart read (score 2): ALEC closed 1.92 (+6.1% per quote, prior close 1.81) at the session high, reclaiming EMA9 1.90, WMA9 1.88, WMA21 1.92 and daily VWAP 1.86 off the 1.73 crash low, but remains below SMA20 1.95, SMA50 2.04 and SMA200 2.00, with MACD line/signal negative (-0.07/-0.06, histogram -0.01) and ADX 22.7 (sub-25, no strong trend; read with price under the SMA stack = down-drift). The tape is a reflex bounce inside the 2026-10-05/10-06 event-driven two-session -37% repricing (89.98M and 10.18M-share days; bounce volume lighter at 3.95M), not a trend-aligned structure. Entry is blocked by the fundamental override (fundamentalScore 2 < 3) and independently by the overnight-gap gate (max 5.05% > 5%); no pullback limit or breakout stop is actionable under these hard blocks.